Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07301255 · ClinicalTrials.gov registry record · Phase 2

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

A Phase 2 study of Asthma, sponsored by Enveda Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
11
Study locations

NCT07301255 is a Phase 2 study of Asthma that is actively recruiting participants, run by Enveda Therapeutics. The registered enrollment target is 50 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07301255, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Enveda Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
11
Study locations

Study Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo
  • DRUG ENV-294

Study Locations (11)

California

  • California Allergy and Asthma Medical - Los Angeles
  • Allergy and Asthma Associates of Santa Clara Valley Research Center - San Jose

Oregon

  • Portland Allergy & Asthma - Clackamas
  • Velocity Clinical Research, Medford - Medford

Alabama

  • AllerVie Clinical Research - Birmingham

Colorado

  • Asthma and Allergy Associates - Colorado Springs

Georgia

  • Georgia Pollens Clinical Research Centers - Albany

Kentucky

  • Allergy & Asthma Specialists - Owensboro

Michigan

  • Revive Research Institute - Southfield

Missouri

  • The Clinical Research Center - St Louis

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-01-09
Est. Completion 2027-01
Phase Phase 2

Sponsor

Enveda Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07301255

The ClinicalTrials.gov registry entry for NCT07301255 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Enveda Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07301255 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Oregon, Alabama.

Frequently Asked Questions

What is clinical trial NCT07301255 about?

NCT07301255 is a clinical study titled "ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults". This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants w...

What is the current status of trial NCT07301255?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-01-09. Estimated completion is 2027-01.

What conditions does trial NCT07301255 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT07301255?

The interventions under investigation include: Placebo (DRUG), ENV-294 (DRUG).

Who is sponsoring clinical trial NCT07301255?

This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07301255 being conducted?

This trial has 11 study locations across Alabama, California, Colorado, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.